SMT201700052T1 - 2-(azaindol-2-il)benzimidazoli come inibitori di pad4 - Google Patents

2-(azaindol-2-il)benzimidazoli come inibitori di pad4

Info

Publication number
SMT201700052T1
SMT201700052T1 SM20170052T SMT201700052T SMT201700052T1 SM T201700052 T1 SMT201700052 T1 SM T201700052T1 SM 20170052 T SM20170052 T SM 20170052T SM T201700052 T SMT201700052 T SM T201700052T SM T201700052 T1 SMT201700052 T1 SM T201700052T1
Authority
SM
San Marino
Prior art keywords
azaindol
benzimidazoles
pad4 inhibitors
pad4
inhibitors
Prior art date
Application number
SM20170052T
Other languages
English (en)
Italian (it)
Inventor
Michael David Barker
John Liddle
Stephen John Atkinson
Matthew Campbell
Hawa Diallo
Clement Douault
Neil Stuart Garton
Robert John Sheppard
Ann Louise Walker
Christopher Wellaway
David Matthew Wilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SMT201700052T1 publication Critical patent/SMT201700052T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM20170052T 2012-07-26 2012-07-26 2-(azaindol-2-il)benzimidazoli come inibitori di pad4 SMT201700052T1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12740581.9A EP2877467B1 (en) 2012-07-26 2012-07-26 2-(azaindol-2-yl)benzimidazoles as pad4 inhibitors
PCT/EP2012/064649 WO2014015905A1 (en) 2012-07-26 2012-07-26 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors

Publications (1)

Publication Number Publication Date
SMT201700052T1 true SMT201700052T1 (it) 2017-03-08

Family

ID=49996626

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20170052T SMT201700052T1 (it) 2012-07-26 2012-07-26 2-(azaindol-2-il)benzimidazoli come inibitori di pad4
SM201700052T SMT201700052B (it) 2012-07-26 2017-01-24 2-(azaindol-2-il)benzimidazoli come inibitori di pad4

Family Applications After (1)

Application Number Title Priority Date Filing Date
SM201700052T SMT201700052B (it) 2012-07-26 2017-01-24 2-(azaindol-2-il)benzimidazoli come inibitori di pad4

Country Status (22)

Country Link
US (4) US9127003B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2877467B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6063567B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101916443B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104470919B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2012386257B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015001545B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2879341C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1118524T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2877467T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2609126T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20161530T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE033294T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014KN02935A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2877467T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2877467T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2877467T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS55684B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2611010C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2877467T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (2) SMT201700052T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014015905A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016185279A1 (en) * 2015-05-21 2016-11-24 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as pad4 inhibitors
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
AR107030A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
MX2018009773A (es) * 2016-02-23 2018-11-29 Padlock Therapeutics Inc Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
CN107188867A (zh) * 2016-03-14 2017-09-22 中国科学院天津工业生物技术研究所 精氨酸脱亚氨酶4的抑制剂
US10703741B2 (en) 2016-07-27 2020-07-07 Padlock Therapeutics, Inc. Covalent inhibitors of PAD4
KR102502992B1 (ko) * 2016-09-12 2023-02-24 패들락 테라퓨틱스, 인코포레이티드 Pad4의 헤테로아릴 억제제
US11208386B2 (en) 2016-12-02 2021-12-28 University Of Massachusetts Inhibitors of protein arginine deiminases (PADs) and methods of preparation and use thereof
CN108689946B (zh) * 2017-04-12 2022-10-18 中国科学院上海药物研究所 2-取代硫基乙酰胺类化合物及其制备方法和应用
CA3073656C (en) * 2017-09-22 2024-03-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
HUE061607T2 (hu) * 2017-10-18 2023-07-28 Jubilant Epipad LLC Imidazopiridin vegyületek mint PAD inhibitorok
MX2020004699A (es) 2017-11-06 2022-10-26 Jubilant Prodel LLC Derivados de pirimidina como inhibidores de la activacion de pd1/pd-l1.
SG11202004537UA (en) 2017-11-24 2020-06-29 Jubilant Episcribe Llc Heterocyclic compounds as prmt5 inhibitors
WO2019161803A1 (zh) * 2018-02-26 2019-08-29 南京药捷安康生物科技有限公司 肽酰精氨酸脱亚胺酶抑制剂及其用途
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
US11524959B1 (en) * 2018-08-08 2022-12-13 Bristol-Myers Squibb Company Indole and azaindole inhibitors of pad enzymes
JP7483678B2 (ja) * 2018-08-08 2024-05-15 ブリストル-マイヤーズ スクイブ カンパニー Pad4阻害剤としての置換ベンズイミダゾール
KR102851932B1 (ko) 2018-08-08 2025-08-27 브리스톨-마이어스 스큅 컴퍼니 Pad4 억제제로서의 치환된 티에노피롤
CN112789087B (zh) * 2018-08-08 2024-08-13 百时美施贵宝公司 Pad酶的苯并咪唑抑制剂
CN109369513B (zh) * 2018-11-20 2020-08-25 都创(上海)医药科技有限公司 一种fbdd常用分子片段的制备方法
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
WO2021003078A1 (en) * 2019-07-03 2021-01-07 University Of Massachusetts Inhibitors of protein arginine deiminase 1 and methods of preparation and use thereof
TW202115083A (zh) * 2019-09-27 2021-04-16 大陸商南京藥捷安康生物科技有限公司 肽醯精胺酸脫亞胺酶抑制劑及其用途
WO2021158840A1 (en) * 2020-02-06 2021-08-12 Bristol-Myers Squibb Company Macrocyclic pad4 inhibitors useful as immunosuppressant
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
CN111265526B (zh) * 2020-04-09 2021-03-19 黑龙江中医药大学 一种治疗胃癌的药物及其制备方法
IL296923A (en) 2020-04-30 2022-12-01 Gilead Sciences Inc Macrocyclic inhibitors of peptidylarginine deiminases
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
WO2022059779A1 (ja) 2020-09-18 2022-03-24 大日本住友製薬株式会社 アミン誘導体
WO2022140390A1 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
TW202233174A (zh) 2020-12-22 2022-09-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
CA3238577A1 (en) 2021-11-15 2023-05-19 Regor Therapeutics, Inc. Pad4 inhibitors and use thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
KR20250027599A (ko) * 2022-05-26 2025-02-26 셀진 코포레이션 헤테로시클릭 pad4 억제제
WO2024109945A1 (en) * 2022-11-24 2024-05-30 Helios Huaming Biopharma Co., Ltd. Selenium containing heterocycle compounds and use thereof
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
EP1870122A3 (en) 1995-04-14 2008-03-12 SmithKline Beecham Corporation Metered dose inhaler
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
CZ2001959A3 (cs) * 1998-09-18 2001-12-12 Basf Aktiengesellschaft 4-Aminopyrrolopyrimidiny jako inhibitory kinasy
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
ES2235970T3 (es) * 1999-10-19 2005-07-16 MERCK & CO. INC. Inhibidores de tirosina quinasa.
KR100755622B1 (ko) 1999-12-24 2007-09-04 아벤티스 파마 리미티드 아자인돌
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
DK1699512T3 (da) 2003-11-03 2012-09-17 Glaxo Group Ltd Fluiddispenseringsindretning
MXPA06005578A (es) 2003-11-17 2006-08-11 Pfizer Prod Inc Compuestos de pirrolopirimidina utiles en el tratamiento del cancer.
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7429611B2 (en) * 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
WO2009042092A1 (en) * 2007-09-25 2009-04-02 Merck & Co., Inc. 2-aryl or heteroaryl indole derivatives
JP2011521961A (ja) 2008-05-28 2011-07-28 ワイス・エルエルシー 3−置換−1H−インドール化合物、mTORキナーゼおよびPI3キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成
RU2011106786A (ru) * 2008-07-23 2012-08-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы пиразолопиридинкиназы
CN104030987B (zh) * 2009-04-02 2017-04-12 默克雪兰诺有限公司 二氢乳清酸脱氢酶抑制剂
WO2010118208A1 (en) 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer

Also Published As

Publication number Publication date
AU2012386257A1 (en) 2015-03-12
AU2012386257B2 (en) 2016-09-08
CN104470919A (zh) 2015-03-25
CA2879341A1 (en) 2014-01-30
JP6063567B2 (ja) 2017-01-18
KR101916443B1 (ko) 2018-11-08
US20160009716A1 (en) 2016-01-14
KR20150038438A (ko) 2015-04-08
US10039755B2 (en) 2018-08-07
US20180161316A1 (en) 2018-06-14
RU2611010C2 (ru) 2017-02-17
US9833449B2 (en) 2017-12-05
SMT201700052B (it) 2017-03-08
ES2609126T3 (es) 2017-04-18
EP2877467A1 (en) 2015-06-03
SI2877467T1 (sl) 2017-02-28
RS55684B1 (sr) 2017-07-31
RU2014152456A (ru) 2016-09-20
LT2877467T (lt) 2017-01-10
BR112015001545B1 (pt) 2022-07-05
IN2014KN02935A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-05-08
US20150175600A1 (en) 2015-06-25
CN104470919B (zh) 2016-07-06
BR112015001545A2 (pt) 2017-07-04
CA2879341C (en) 2019-06-11
US9518054B2 (en) 2016-12-13
HRP20161530T1 (hr) 2017-02-10
JP2015522628A (ja) 2015-08-06
US20170119750A1 (en) 2017-05-04
EP2877467B1 (en) 2016-11-02
HUE033294T2 (en) 2017-11-28
US9127003B2 (en) 2015-09-08
PT2877467T (pt) 2017-01-02
PL2877467T3 (pl) 2017-08-31
WO2014015905A1 (en) 2014-01-30
CY1118524T1 (el) 2017-07-12
DK2877467T3 (en) 2017-02-13

Similar Documents

Publication Publication Date Title
PL2877467T3 (pl) 2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4
IL239193A0 (en) New Benzimidazole Derivatives as Kinase Inhibitors
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
RS58892B1 (sr) Jedinjenja 3-aminocikloalkila kao inhibitori ror-gama-t i njihove upotrebe
IL239278A0 (en) Heterocyclic compound
IL237475A0 (en) Pyrlotriazinone derivatives as pi3k inhibitors
EP2832734A4 (en) HETEROCYCLIC COMPOUND
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
ZA201406225B (en) Thiadiazolidinediones as gsk-3 inhibitors
LT2912041T (lt) Tetrahidropiroltiazino dariniai kaip bace slopikliai
EP2866893A4 (en) HETEROCYCLIC GUANIDINE F1FO ATPASE INHIBITORS
IL235919A0 (en) inhibitors of fbxo3